What You Ought to Know:
– OpenEvidence, probably the most broadly used medical search and AI application amongst verified U.S. clinicians raises $210M in Collection B funding spherical, valuing the corporate at $3.5 billion. The spherical was co-led by Google Ventures and Kleiner Perkins, with follow-on funding from Collection A pacesetter Sequoia Capital, and extra participation from Coatue, Conviction, and Thrive. OpenEvidence has now raised over $300M since its founding.
– OpenEvidence is quickly reworking how frontline healthcare suppliers entry, consider, and apply the world’s medical data, serving to clinicians make high-stakes scientific selections on the level of care.
Fixing Data Overload with Actual-Time Proof
Clinicians are overwhelmed by info overload, with the quantity of medical analysis doubling each 5 years. Conventional medical proof databases are sluggish, fragmented, and require intensive handbook looking out, pulling physicians away from affected person care.
OpenEvidence addresses this by permitting clinicians to “search as soon as, skip the scavenger hunt, and floor the science in seconds”. By way of strategic content material partnerships with establishments just like the American Medical Affiliation (JAMA) and The New England Journal of Drugs, OpenEvidence gives point-of-care solutions grounded within the newest analysis, full with references and follow-up strategies. OpenEvidence’s HIPAA-compliant platform quickly synthesizes medical analysis, enabling quicker, extra evidence-based selections and improved affected person outcomes by lowering the lag between new proof and bedside software.
Launching DeepConsult™: The First AI Agent for Physicians
Along with the funding announcement, OpenEvidence introduced the extensive launch of OpenEvidence DeepConsult™, the primary AI agent purpose-built for physicians. DeepConsult gives each doctor with a private, non-public staff of PhD-level, medically-specialized AI brokers able to conducting superior medical analysis autonomously.
These DeepConsult brokers use superior reasoning fashions to investigate and cross-reference a whole lot of peer-reviewed medical research in parallel, surfacing not simply direct solutions but additionally novel, cross-cutting connections which may in any other case go unnoticed. This leads to an evidence-based synthesis—an integrative, interdisciplinary understanding distilled from a whole lot of research that will sometimes take a human researcher months to supply for a single scientific subject.
Whereas OpenEvidence’s core search product focuses on velocity (5–10 second solutions), DeepConsult addresses a special use case: offering complete analysis reviews for advanced questions when physicians have extra time, akin to throughout a lunch break. This marks a brand new period of medical productiveness with tireless, agentic assistants.
Regardless of DeepConsult runs requiring over 100 instances the compute and price of a normal search, OpenEvidence is providing it solely free to all verified U.S. clinicians, no matter their establishment or office, underscoring its mission to help physicians on the level of care.
Progress and Medical Adoption
OpenEvidence is actively used throughout greater than 10,000 hospitals and medical facilities nationwide and by over 40% of physicians in america who log in day by day. The platform continues to develop by over 65,000 new verified U.S. clinician registrations every month.
The corporate has seen exponential development: in July 2024, OpenEvidence supported roughly 358,000 logged-in, verified U.S. doctor consultations in a single month. One 12 months later, OpenEvidence now handles that many consultations every workday, supporting over 8,500,000 scientific consultations by logged-in, verified U.S. physicians per thirty days—a 2,000%+ year-over-year development fee. Greater than 100 million People this 12 months can be handled by a health care provider who used OpenEvidence.
Enlargement Plans
OpenEvidence, based by Harvard- and MIT-trained PhDs Daniel Nadler and Zachary Ziegler, will use the brand new funding to broaden strategic content material partnerships that improve its library of superior medical data. Daniel Nadler, founding father of Kensho (acquired by S&P World for $700 million in 2018), was additionally named to the TIME100 Well being listing of the 100 Most Influential Folks in world well being in 2025. Robert M. Wachter, MD, Chair of Drugs at UCSF, lauded the partnership with the American Medical Affiliation as a big step in the direction of fulfilling the promise of trusted, evidence-based scientific determination help.
